After finishing at $11.69 in the prior trading day, Cellebrite DI Ltd (NASDAQ: CLBT) closed at $11.68, down -0.09%. In other words, the price has decreased by -$0.01 from its previous closing price. On the day, 941312 shares were traded.
Ratios:
Our goal is to gain a better understanding of CLBT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.93. For the most recent quarter (mrq), Quick Ratio is recorded 1.62 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.27.
On February 16, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $9 to $12.
On July 19, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $11.Craig Hallum initiated its Buy rating on July 19, 2023, with a $11 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 2.31B and an Enterprise Value of 2.02B. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.09 while its Price-to-Book (P/B) ratio in mrq is 60.76. Its current Enterprise Value per Revenue stands at 6.20 whereas that against EBITDA is 46.63.
Stock Price History:
Over the past 52 weeks, CLBT has reached a high of $12.50, while it has fallen to a 52-week low of $5.22. The 50-Day Moving Average of the stock is 10.30, while the 200-Day Moving Average is calculated to be 8.21.
Shares Statistics:
The stock has traded on average 977.44K shares per day over the past 3-months and 1.08M shares per day over the last 10 days, according to various share statistics. A total of 187.68M shares are outstanding, with a floating share count of 53.43M. Insiders hold about 72.93% of the company’s shares, while institutions hold 26.51% stake in the company. Shares short for CLBT as of Feb 29, 2024 were 2.35M with a Short Ratio of 2.40, compared to 2.66M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.19% and a Short% of Float of 3.94%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of $0.06 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.05, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.07, with high estimates of $0.08 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.34 and $0.29 for the fiscal current year, implying an average EPS of $0.31. EPS for the following year is $0.39, with 5 analysts recommending between $0.43 and $0.34.
Revenue Estimates
6 analysts predict $85.59M in revenue for the current quarter. It ranges from a high estimate of $88M to a low estimate of $84.02M. As of the current estimate, Cellebrite DI Ltd’s year-ago sales were $71.23M, an estimated increase of 20.20% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $90.28M, an increase of 17.70% less than the figure of $20.20% in the same quarter last year. There is a high estimate of $91.12M for the next quarter, whereas the lowest estimate is $89.11M.
A total of 7 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $380M, while the lowest revenue estimate was $375.02M, resulting in an average revenue estimate of $376.82M. In the same quarter a year ago, actual revenue was $325.11M, up 15.90% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $449.06M in the next fiscal year. The high estimate is $467M and the low estimate is $433.2M. The average revenue growth estimate for next year is up 19.20% from the average revenue estimate for this year.
